Cellcolabs, a Stockholm-based BioTech startup focused on industrial-scale production of mesenchymal stem cells (MSCs), has secured €10.3 million in new funding to support further technical development, production scaling, and global market expansion.
The investment was led by Titian Capital through its life sciences platform, Titian Life Sciences, and brings Cellcolabs’ total funding to €31 million.
Dr Mattias Bernow, CEO of Cellcolabs, comments: “The industry is reaching an inflexion point. Scientific evidence is mounting. Regulatory pathways are opening. The demand for stem cells has never been greater. Yet scalable access remains the missing piece.”
Comparable developments include Finland’s StemSight, which raised €2.3 million to progress stem-cell-based treatments for corneal blindness, and Denmark’s Fuse Vectors, which secured €4.9 million for its cell-free viral vector platform supporting gene therapy production.
Larger later-stage activity is also evident with the UK’s TRIMTECH Therapeutics raising €28.6 million for neurodegenerative disease treatments, and LIfT BioSciences receiving €12 million to scale its allogeneic neutrophil immunotherapy platform.
While other Nordic firms such as StemSight and Fuse Vectors highlight the regional strength in advanced therapy development, Cellcolabs appears to represent one of Sweden’s most substantial 2025 fundraises in regenerative medicine – signalling growing European confidence in scalable stem-cell production as a foundation for the next generation of clinical and research applications.
“The partnership with Titian Life Sciences provides Cellcolabs with both the capital and strategic footprint needed to grow internationally. Together, we are building the infrastructure that can make stem cell therapies widely available, not someday, but in our lifetime,” adds Dr Bernow.
Founded in 2021 by Dr Mattias Bernow, Cellcolabs aims to revolutionise access to regenerative medicine by making high-quality, GMP-certified stem cells widely available and affordable. The startup is setting its sights on reducing the cost of MSCs by 90% by 2035, a move that would significantly lower barriers for both research and therapeutic use.
The company currently operates a GMP-certified facility in Stockholm and provides allogeneic MSCs to hospitals, academic institutions, and private clients globally. Its clients include professional athletes and public figures.
The MSCs are also used in studies focusing on musculoskeletal repair, cardiovascular prevention, and age-related frailty – though Cellcolabs itself does not administer treatments. These studies are often supported by the company’s subsidiary.
Inspired by two decades of stem cell research at Sweden’s Karolinska Institutet, Cellcolabs developed a proprietary protocol for producing MSCs at scale, using a method that prioritises both scientific rigour and industrial consistency. This protocol is said to offer an edge over larger players such as Lonza Group, Thermo Fisher Scientific, and Stemcell Technologies, who still rely on smaller-scale, less standardised manufacturing.
Kayaan Unwalla, Managing Director of Titian Capital, adds: “The field of regenerative medicine is entering a new era. Our investment in Cellcolabs reflects Titian Capital’s conviction that scalable, standardised production of GMP-grade stem cells will be fundamental to the future of medicine. We are delighted to support Cellcolabs’ expansion and, in doing so, we aim to accelerate the global accessibility of safe, high-quality cellular therapies and help translate cutting-edge science into transformative patient outcomes.”
According to data from Crunchbase, the company had a previous €8 million funding round in March 2024.
EU-Startups previously featured Cellcolabs in its July 2024 roundup of “10 promising European startups focusing on biopharmaceuticals”, recognising the firm as an emerging player in regenerative medicine and large-scale stem cell production.
The company’s ultimate ambition is to industrialise stem cell production so that research facilities and healthcare systems no longer need to rely on bespoke or small-batch alternatives.
Cellcolabs’ entry into the space comes at a time when demand for regenerative therapies is climbing steeply but remains underserved due to the high costs and manufacturing bottlenecks. With its streamlined and scalable platform, the company is positioning itself to lead a new generation of BioTech solutions capable of delivering consistent, safe, and affordable cellular therapies at global scale.
Read the orginal article: https://www.eu-startups.com/2025/10/e10-3-million-boost-for-swedens-cellcolabs-to-lower-global-stem-cell-costs-by-90-through-scalable-manufacturing/
